Rochester,NY 7/15/2009 8:00:29 PM
MRK - UPDATE 2-FDA gives Consent To widen the usage of Isentress HIV drug developed by Merck
MERCK CO INC
MERCK CO INC, MRK
WhisperFromWallStreet.com offers daily stock alerts to subscribers. Sign up for our free alerts newsletter.
Merck & Co on Thursday said U.S. regulators had widened the approved use of its Isentress HIV treatment to include patients who have not yet been treated for infections with the virus that causes AIDS. Isentress, the only approved member of a new family of anti-HIV medicines known as integrase inhibitors, has been available since late 2007 for patients who have failed to benefit from prior treatment with HIV medicines. The new indication could help boost sales of the drug, which posted revenue last year of $361 million and is often used with the widely prescribed combination treatment Truvada sold by Gilead Sciences Inc.
About WhisperFromWallStreet.com
WhisperfromWallStreet.com is a FREE award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, as well as teaching you how to become a better trader. We scan hundreds of stocks a day to find those that meet our criteria and when we find one, we send you an alert.
Sign up for our FREE alerts newsletter at WhisperfromWallStreet.com
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
